Evidence-Based Reviews

Rediscovering clozapine: After a turbulent history, current guidance on initiating and monitoring

Current Psychiatry. 2016 July;15(7):42-46,48-49

References

1. Stroup TS, Gerhard T, Crystal S, et al. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65(2):186-192.
2. Olfson M, Gerhard T, Crystal S, et al. Clozapine for schizophrenia: state variation in evidence-based practice. Psychiatr Serv. 2016;67(2):152.
3. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
4. Cetin M. Clozaphobia: fear of prescribers of clozapine for treatment of schizophrenia. Klinik Psikofarmakol Bulteni. 2014;24(4):295-301.
5. Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999;60(suppl 12):22-23.
6. Amsler HA, Teerenhovi L, Barth E, et al. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand. 1977;56(4):241-248.
7. Crilly J. The history of clozapine and its emergence in the U.S. market: a review and analysis. Hist Psychiatry. 2007;18(1):39-60.
8. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 1987;7(6):377-384.
9. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
10. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA modified monitoring for neutropenia associated with schizophrenia medicine clozapine; approves new shared REMS program for all clozapine medicines. http://www.fda.gov/Drugs/DrugSafety/ucm461853.htm. Published September 15, 2015. Accessed November 23, 2015.
11. Clozapine REMS Program. What’s new with clozapine: an overview. https://www.clozapinerems.com/CpmgClozapineUI/rems/pdf/WhatsNEWwithClozapine_An%20Overview.pdf. Published September 2015. Accessed November 23, 2015.
12. Clozapine REMS Program. Clozapine and the risk of neutropenia: a guide for healthcare providers. https://www.clozapinerems.com/CpmgClozapineUI/rems/pdf/resources/Clozapine_REMS_HCP_Guide.pdf. Published September 2015. Accessed November 23, 2015.
13. Novartis Pharmaceuticals Corporation. Clozaril (clozapine). Prescribing information. http://clozaril.com/wp-content/themes/eyesite/pi/Clozaril-2015A507-10022015-Approved.pdf. Accessed June 16, 2016.
14. Newman WJ. Psychopharmacologic management of aggression. Psychiatr Clin North Am. 2012;35(4):957-972.
15. Ifteni P, Nielsen J, Burtea V, et al. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand. 2014;130(1):25-29.
16. Hsieh MM, Tisdale JF, Rodgers GP, et al. Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol. 2010;28(10):1633-1637.

Rediscovering clozapine: After a turbulent history, current guidance on initiating and monitoring

References

Pages

Recommended Reading